Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Feature: All Finviz Members Now Get Real-Time Earnings Data

Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?

By Zacks Equity Research | July 23, 2025, 9:57 AM

Vertex Pharmaceuticals Inc

Zai Lab Limited ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Vertex Pharmaceuticals Inc

Zai Lab Limited ADR

Latest News

11 hours	Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial VRTX FinanceWire
Sep-29	Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) ZLAB Business Wire
Sep-24	Lillys latest China drug deal; Immunovants setback in lupus VRTX BioPharma Dive
Sep-23	Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage VRTX InvestorsHub
Sep-22	The Surprise That Sent Vertex - And Its Chief Rival - Soaring VRTX Investor's Business Daily
Sep-22	Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder VRTX Stocktwits
Sep-22	Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech VRTX Barrons.com
Sep-22	Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial VRTX Business Wire
Sep-17	Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout VRTX Investor's Business Daily
Sep-15	Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results VRTX Barrons.com
Sep-15	Vera Makes A Bullish Move - Times Three. Will It Hold Up To Competition? VRTX Investor's Business Daily
Sep-15	Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain VRTX Business Wire
Sep-11	Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher VRTX FX Empire
Sep-01	Goldman Sachs refreshes conviction lists on both sides of the Atlantic VRTX Investing.com
Sep-01	Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform VRTX InvestorsHub

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)